Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAX | P61244 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2785911 | 1.00 | PTPN1 (0.47) | PTPN1CISD1MAOBCA9GAA | |
| SCHEMBL2172007 | 0.89 | MCL1 (0.44) | PTPN1MYCMAXS1PR1S1PR3 | |
| SCHEMBL2171003 | 0.89 | AKR1B1 (0.47) | PPARGS1PR1S1PR3MCL1ESR1 | |
| SCHEMBL2786612 | 0.89 | MCL1 (0.44) | PTPN1MYCMAXS1PR1S1PR3 | |
| SCHEMBL2784557 | 0.89 | AKR1B1 (0.47) | PPARGS1PR1S1PR3MCL1ESR1 | |
| SCHEMBL2173147 | 0.88 | MCL1 (0.57) | PTPN1MAOBS1PR1S1PR3MCL1 | |
| SCHEMBL2172867 | 0.88 | MCL1 (0.44) | PTPN1MCL1ALDH1A1HPGDMEN1 | |
| SCHEMBL2784736 | 0.88 | MCL1 (0.57) | PTPN1MAOBS1PR1S1PR3MCL1 | |
| SCHEMBL2786112 | 0.87 | AURKA (0.43) | PTPN1CA9PPARGESR1ESR2 | |
| SCHEMBL2172237 | 0.87 | AURKA (0.43) | PTPN1CA9PPARGESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | claimed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | claimed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | PTPN1 2303/4885CISD1 1747/4885MAOB 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.